ClinicalTrials.Veeva

Menu

Tapping Test and the Archimedean Spiral for the Differential Diagnosis of Tremor. Machine Learning Approach (MATSEP)

C

Consorci Sanitari de l'Alt Penedès i Garraf

Status

Enrolling

Conditions

Tremor
Essential Tremor
Parkinson Disease

Treatments

Diagnostic Test: Tapping Test
Diagnostic Test: Archimedes Spiral

Study type

Observational

Funder types

Other

Identifiers

NCT06378619
CSAPG-50

Details and patient eligibility

About

In clinical practice, it is sometimes difficult to establish whether a patient's tremor is due to Parkinson's disease or essential tremor. The distinction is crucial as the health implications differ significantly between the two conditions. Therefore, the present study aims to develop a diagnostic method based on machine learning techniques to help differentiate whether a patient's tremor is due to one condition or the other. To achieve this, 110 patients with tremor, correctly diagnosed with either Parkinson's disease or essential tremor, will participate. They will undergo two diagnostic tests (tapping test and Archimedean spiral) to capture data that can be processed using machine learning techniques.

Enrollment

110 estimated patients

Sex

All

Ages

45 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Possibility to collaborate in the necessary evaluations.
  • Follow-up in the specialized consultation of Movement Disorders at the Neurology Service of Hospital Sant Camil-Consorci Sanitari Alt Penedes i Garraf.
  • Legal capacity to provide informed consent.
  • Signature of informed consent for study inclusion, either by the participant themselves or by their legal representative.
  • Participant with criteria from Group 1 or 2:

Group 1:

  • Confirmed diagnosis of tremor due to Parkinson's disease, clinically established, based on the diagnostic criteria of the Movement Disorders Society, and additionally:
  • Tremor associated with bradykinesia of any duration.
  • Confirmatory clinical diagnosis of tremor due to Parkinson's disease (stages 1 to 2 of Hoehn and Yahr) by the neurologist responsible for the participant's follow-up.

Group 2:

  • Confirmed diagnosis of essential tremor, based on the criteria of the Movement Disorders Society, and additionally:
  • Positional tremor plus kinetic and/or resting tremor with follow-up in outpatient neurology consultations for at least 3 years without a change in diagnosis.
  • Absence of bradykinesia.

Exclusion criteria

  • Patients undergoing treatment with antipsychotics or antidepressants.
  • Patients with Parkinson's disease and dyskinesias.
  • Patients undergoing treatment with dopaminergic agonists or primidone.
  • Tremor of such severity that it prevents continuous tracing, at the investigator's discretion.
  • Cognitive or affective pathology that limits the ability to collaborate with the study procedures.
  • Participation in another clinical study involving an intervention, procedure, or visit frequency that is incompatible with the present study.
  • Participants diagnosed with any of the following conditions:

Alcoholism of sufficient intensity to influence handwriting or cause neuropathy, at the investigator's discretion. Peripheral neuropathy of any cause. Dystonias. Previous stroke.

Trial design

110 participants in 2 patient groups

Essential Tremor
Description:
Tris group will include 55 participants affected by essential tremor
Treatment:
Diagnostic Test: Archimedes Spiral
Diagnostic Test: Tapping Test
Parkinson Disease
Description:
Tris group will include 55 participants affected by Parkinson Disease
Treatment:
Diagnostic Test: Archimedes Spiral
Diagnostic Test: Tapping Test

Trial contacts and locations

1

Loading...

Central trial contact

Noemí Casaponsa; José Luis Camacho, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems